Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Alberta Cancer Board |
---|---|
Information provided by: | Alberta Cancer Board |
ClinicalTrials.gov Identifier: | NCT00123760 |
Positron Emission Tomography (PET) is a specialised nuclear medicine procedure that uses positron emitting radiolabeled tracer molecules to measure biological activity. The most common of these radiolabeled tracers is 18F-fluorodeoxyglucose (18F-FDG), which is used to determine abnormal glucose metabolism in tumours and other sites. It has general applications in all areas where abnormal glucose metabolism may be present including in circumstances such as differentiating the tumour from scar tissue; evaluating the presence of the tumour in light of rising tumour markers and normal morphological imaging techniques; and assessing response to therapy where other techniques are deemed to be unhelpful. The Cross Cancer Institute (CCI) has recently been funded to establish a PET centre, and this study will prove the effectiveness of PET scanning in the Canadian health care environment and validate the data that have been developed in other jurisdictions in specific oncologic indications.
Condition | Intervention | Phase |
---|---|---|
Brain Neoplasms Lung Neoplasms Thyroid Neoplasms Colorectal Neoplasms Lymphoma |
Procedure: Positron Emission Tomography (PET) scan |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | A Phase I/II, Phase III and Extended Phase III Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer |
Estimated Enrollment: | 3500 |
Study Start Date: | February 2004 |
Estimated Study Completion Date: | July 2009 |
Ages Eligible for Study: | 15 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Alexander McEwan, MB, MSc, MD, FRCP | 780-432-8524 | sandymce@cancerboard.ab.ca |
Canada, Alberta | |
Cross Cancer Institute | Recruiting |
Edmonton, Alberta, Canada, T6G 1Z2 | |
Contact: Clinical Research Unit 780-989-8152 clinical_trials_cci@cancerboard.ab.ca | |
Principal Investigator: Alexander McEwan, MB, MSc, MD, FRCP |
Principal Investigator: | Alexander McEwan, MB, MSc, MD, FRCP | Alberta Cancer Board |
Study ID Numbers: | SP-11-0035 |
Study First Received: | July 22, 2005 |
Last Updated: | September 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00123760 |
Health Authority: | Canada: Health Canada |
Positron-Emission Tomography Fluorodeoxyglucose F18 Tomography scanners, X-Ray computed |
Thoracic Neoplasms Gastrointestinal Diseases Colonic Diseases Central Nervous System Neoplasms Brain Diseases Rectal Diseases Respiratory Tract Diseases Lung Neoplasms Lymphoma Thyroid Diseases Nervous System Neoplasms Endocrine Gland Neoplasms Immunoproliferative Disorders Digestive System Neoplasms Thyroid Neoplasms |
Endocrine System Diseases Central Nervous System Diseases Intestinal Diseases Intestinal Neoplasms Lymphatic Diseases Brain Neoplasms Digestive System Diseases Head and Neck Neoplasms Lung Diseases Deoxyglucose Gastrointestinal Neoplasms Endocrinopathy Lymphoproliferative Disorders Colorectal Neoplasms |
Antimetabolites Anti-Infective Agents Respiratory Tract Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site |
Molecular Mechanisms of Pharmacological Action Immune System Diseases Therapeutic Uses Nervous System Diseases Antiviral Agents Pharmacologic Actions |